Hydrophilic vs hydrophobic: which is the better option?

Article

Dr Christophe Chassain believes blue-blocking square-edged hydrophilic lenses are just as safe as their hydrophobic counterparts

Hydrophilic vs hydrophobic: which is the better option?

"Hydrophilic IOLs tend to be easier for the surgeon to implant, and are therefore, particularly in the case of very small incisions, probably a more suitable surgical option than hydrophobic IOLs," said Christophe Chassain, MD, an anterior segment surgeon at the Clinique Beau-Soleil, Montpellier, France. "Postoperatively, though, hydrophilic lenses have a worse reputation for prevention of posterior capsule opacification (PCO), which traditionally has been a prime metric used to determine the success of IOL implantation."

Related: Posterior corneal elevation: Is there a role for premium IOLs?

PCO: investigating hydrophilic IOLs

The SlimFlex is a 26% hydrophilic monobloc IOL with a 6 mm optic, and a 360° posterior square edge. It has an overall diameter of 10.5 mm, with four haptics at a 5° angle. The lens can be injected through a 2.4 mm incision. MicroSLIM - the microincision version of the lens, which can be injected through a 1.8 mm incision - is made from 25% hydrophilic material.

Dr Chassain implanted 344 SlimFlex lenses into 191 female and 153 male subjects with a mean age of 77 years (range: 46–94 years) and a mean dioptric power of +20.5 D (range: 9–28 D). Topical anaesthesia was used and, during the coaxial surgery, the posterior capsule was cleaned; FlexiRing intracapsular rings (IOLTECH Laboratories) were implanted into 34 eyes. A rhexis of 5.5 mm was achieved in 66% of cases; the rhexis IN position was 76% with an optic overlap.

Related: No toric? No problem: Small-aperture optics can mitigate astigmatism

Similar PCO rates with both lens types

"Of the 344 subjects implanted with the SlimFlex lens, 3.2% required further treatment with Nd:YAG posterior capsulotomy to combat PCO. Of these, four YAGs were performed in the 180 eyes with an IN rhexis; six in the 57 eyes with an IN/OUT rhexis; one in the four eyes with posterior fibrosis, and two in the 34 eyes implanted with a FlexiRing," reported Dr Chassain.

The mean follow-up period was 20.6 months (range: 11–28 months). At this stage, 68.6% of subjects had achieved a clear central posterior capsule.

Related Content: Cataract & Refractive | Inflammation & Infection | Cornea

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.